dbPepNeo

dbPepNeo catalogs human tumor neoantigen peptides and their experimental validation to support cancer immunology research and the development and evaluation of cancer immunotherapies.

Key Features:

• Curated Neoantigen Collection: Compiles experimentally validated neoantigen peptides that bind human leukocyte antigen class I (HLA-I) identified from human tumors.
• Experimental Validation Methods: Includes peptides validated by mass spectrometry (MS) and immunoassays performed on human tumor samples.
• Confidence Classification: Categorizes peptides into High (295 peptides), Medium (247 peptides), and Low (407,794 peptides) confidence levels based on experimental verification.

Scientific Applications:

• Neoantigen Screening: Provides a validated peptide repository for screening and prioritizing candidate neoantigens for cancer immunotherapy.
• Optimization of Prediction Pipelines: Supplies experimentally validated data to refine and evaluate computational neoantigen prediction pipelines.
• T-cell Receptor (TCR) Recognition Studies: Supports investigation of TCR recognition mechanisms using curated neoantigen peptides.

Methodology:

Collection and classification of neoantigen peptides based on experimental validation from human tumors using mass spectrometry (MS) and immunoassays.